Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 8/20 | 0.58 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | KDM1A | O60341 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14595387 | 0.83 | HSD11B1 (0.63) | HSD11B1ALDH1A1KDM4E | |
| SCHEMBL10510729 | 0.82 | HRH3 (0.49) | HSD11B1HRH3ALDH1A1 | |
| SCHEMBL7903517 | 0.73 | HSD11B1 (0.82) | HSD11B1ALDH1A1KDM4EKMT2A | |
| SCHEMBL2748651 | 0.72 | KDM4E (0.53) | HSD11B1ALDH1A1KDM4E | |
| SCHEMBL7389926 | 0.72 | SMN1; SMN2 (0.42) | ALDH1A1KMT2A | |
| SCHEMBL25561906 | 0.71 | HSD11B1 (0.62) | HSD11B1ALDH1A1KDM4EKMT2A | |
| SCHEMBL20381220 | 0.71 | HSD11B1 (0.54) | HSD11B1HRH3KMT2A | |
| SCHEMBL12632673 | 0.70 | HSD11B1 (0.89) | HSD11B1ALDH1A1KDM4EKMT2A | |
| SCHEMBL20381970 | 0.70 | HSD11B1 (0.96) | HSD11B1ALDH1A1KMT2A | |
| SCHEMBL5513698 | 0.70 | HSD11B1 (0.52) | HSD11B1ALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070015766-A1 | Quinoline Derivatives as NK-3 and NK-2 Antagonists | GlaxoSmithKline S.P.A. & Laboratoire | 2007-01-18 | — | — | US | disclosed |
| US-20070015766-A1 | Quinoline Derivatives as NK-3 and NK-2 Antagonists | GlaxoSmithKline S.P.A. & Laboratoire | 2007-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070015766-A1 | Quinoline Derivatives as NK-3 and NK-2 Antagonists | KCNK3, KCNQ3, ACKR3 | HSD11B1 2234/4885HRH3 7/4885ALDH1A1 3182/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.